This vector is similar to the one currently being used in clinical trials for CLN6 disease patients (Cain et al., 2019), with the substitution of the more moderately expressing Mecp2 promoter for the previously used CMV enhanced chicken-β-actin (CB) promoter. Here, ACTB is linked to CLN6 disease.